WO2020197101A3 - 이중 약물 방출을 위한 약물 전달체 - Google Patents
이중 약물 방출을 위한 약물 전달체 Download PDFInfo
- Publication number
- WO2020197101A3 WO2020197101A3 PCT/KR2020/002545 KR2020002545W WO2020197101A3 WO 2020197101 A3 WO2020197101 A3 WO 2020197101A3 KR 2020002545 W KR2020002545 W KR 2020002545W WO 2020197101 A3 WO2020197101 A3 WO 2020197101A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- drug
- dual
- carrier
- release
- drug carrier
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Nanotechnology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
본 발명은 이중 약물 방출을 위한 약물 전달체에 관한 것으로, 더욱 상세하게는 제1 약물과 제1 생체 적합성 고분자가 혼합된 코어 로드(core rod) 및, 제2 약물과 제2 생체 적합성 고분자가 혼입된 쉘(shell) 구조에 의해 약물이 순차적으로 방출될 뿐만 아니라 지속적으로 방출될 수 있는 약물 전달체에 관한 것이다. 본 발명에 따른 약물 전달체에 따르면, 이중 약물이 순차적/지속적으로 방출될 수 있도록 함으로써 약물 투여 횟수를 줄일 수 있으며, 이에 따라 부작용도 최소화할 수 있다.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2019-0034479 | 2019-03-26 | ||
KR1020190034479A KR102183669B1 (ko) | 2019-03-26 | 2019-03-26 | 이중 약물 방출을 위한 약물 전달체 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2020197101A2 WO2020197101A2 (ko) | 2020-10-01 |
WO2020197101A3 true WO2020197101A3 (ko) | 2020-11-19 |
Family
ID=72612070
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2020/002545 WO2020197101A2 (ko) | 2019-03-26 | 2020-02-21 | 이중 약물 방출을 위한 약물 전달체 |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR102183669B1 (ko) |
WO (1) | WO2020197101A2 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102637156B1 (ko) * | 2021-11-05 | 2024-02-16 | 주식회사 지투지바이오 | 비경구 병용투여용 약학적 키트 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011035013A2 (en) * | 2009-09-17 | 2011-03-24 | Surmodics Pharmaceuticals, Inc. | Implant devices that differ by release profile and methods of making and using same |
WO2011037955A1 (en) * | 2009-09-22 | 2011-03-31 | Surmodics Pharmaceuticals, Inc. | Implant devices for modulating bioactive agent release profiles |
WO2011037953A2 (en) * | 2009-09-22 | 2011-03-31 | Surmodics Pharmaceuticals, Inc. | Implant devices having varying bioactive agent loading configurations |
WO2011116132A1 (en) * | 2010-03-16 | 2011-09-22 | Titan Pharmaceuticals, Inc. | Heterogeneous implantable devices for drug delivery |
KR20110118859A (ko) * | 2010-04-26 | 2011-11-02 | 한국과학기술연구원 | 코어-쉘 구조의 성장인자 전달체, 그의 제조방법 및 세포 분화 또는 증식을 위한 그의 용도 |
KR20160083779A (ko) * | 2014-12-31 | 2016-07-12 | 중앙대학교 산학협력단 | 약물 방출 조절이 가능한 스캐폴드 |
US9572780B2 (en) * | 2003-07-18 | 2017-02-21 | Depomed, Inc. | Dual drug dosage forms with improved separation of drugs |
US20180264179A1 (en) * | 2017-03-19 | 2018-09-20 | Biohealthways, Inc. | Biodegrading implantable ocular sustained release drug delivery system |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101809939B1 (ko) | 2016-09-27 | 2017-12-18 | 울산과학기술원 | 친수성 및 소수성 약물의 순차적 방출을 위한 나노 약물 전달체 |
-
2019
- 2019-03-26 KR KR1020190034479A patent/KR102183669B1/ko active IP Right Grant
-
2020
- 2020-02-21 WO PCT/KR2020/002545 patent/WO2020197101A2/ko active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9572780B2 (en) * | 2003-07-18 | 2017-02-21 | Depomed, Inc. | Dual drug dosage forms with improved separation of drugs |
WO2011035013A2 (en) * | 2009-09-17 | 2011-03-24 | Surmodics Pharmaceuticals, Inc. | Implant devices that differ by release profile and methods of making and using same |
WO2011037955A1 (en) * | 2009-09-22 | 2011-03-31 | Surmodics Pharmaceuticals, Inc. | Implant devices for modulating bioactive agent release profiles |
WO2011037953A2 (en) * | 2009-09-22 | 2011-03-31 | Surmodics Pharmaceuticals, Inc. | Implant devices having varying bioactive agent loading configurations |
WO2011116132A1 (en) * | 2010-03-16 | 2011-09-22 | Titan Pharmaceuticals, Inc. | Heterogeneous implantable devices for drug delivery |
KR20110118859A (ko) * | 2010-04-26 | 2011-11-02 | 한국과학기술연구원 | 코어-쉘 구조의 성장인자 전달체, 그의 제조방법 및 세포 분화 또는 증식을 위한 그의 용도 |
KR20160083779A (ko) * | 2014-12-31 | 2016-07-12 | 중앙대학교 산학협력단 | 약물 방출 조절이 가능한 스캐폴드 |
US20180264179A1 (en) * | 2017-03-19 | 2018-09-20 | Biohealthways, Inc. | Biodegrading implantable ocular sustained release drug delivery system |
Non-Patent Citations (1)
Title |
---|
DE SOUZA, S. O. ET AL.: "Biodegradable core-shell electrospun nanofibers containing bevacizumab to treat age-related macular degeneration", JOURNAL OF MATERIALS SCIENCE : MATERIALS IN MEDICINE, vol. 29, no. 173, 2018, pages 1 - 11, XP036652818, DOI: 10.1007/s10856-018-6187-5 * |
Also Published As
Publication number | Publication date |
---|---|
KR20200113784A (ko) | 2020-10-07 |
WO2020197101A2 (ko) | 2020-10-01 |
KR102183669B1 (ko) | 2020-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009063222A3 (en) | Solid compositions | |
WO2005041968A3 (en) | Once-a-day, oral, controlled-release, oxycodone dosage forms | |
WO2010115552A8 (en) | Bispecific anti-erbb-3/anti-c-met antibodies | |
MX356111B (es) | Composiciones farmaceuticas disuasorias de abuso, de liberacion inmediata. | |
WO2006125620A3 (en) | Cores and microcapsules suitable for parenteral administration as well as process for their manufacture | |
MX349917B (es) | Composiciones farmaceuticas que comprneden pilocarpina. | |
WO2007144169A3 (en) | Entacapone-derivatives | |
MD3310345T2 (ro) | Comprimată orodispersabilă ce conține estetrol | |
WO2008016677A3 (en) | Preparation and utility of deuterated amphetamines | |
WO2010043408A3 (de) | Mikroverkapseltes fesoterodin | |
WO2010127205A3 (en) | Fixed dose drug combination formulations | |
RU2014129508A (ru) | Новая комбинация | |
WO2020138791A3 (ko) | 토파시티닙 또는 그의 약제학적으로 허용되는 염을 함유한 서방성 제제 및 그의 제조방법 | |
WO2020197101A3 (ko) | 이중 약물 방출을 위한 약물 전달체 | |
WO2019212356A8 (en) | Tetrazines for high click conjugation yield in vivo and high click release yield | |
WO2010149196A8 (en) | Taste masked dosage form of pharmaceutically acceptable salt of escitalopram | |
WO2012002773A3 (en) | Phenylcarbamate compound and muscle relaxant containing the same | |
MX2019010228A (es) | Composición para liberación controlada de sustancias fisiológicamente activas y proceso para su preparación. | |
WO2012099899A3 (en) | Topical dermatological compositions for the treatment of acne | |
EP3978027A4 (en) | PHYSIOLOGICALLY ACTIVE SUBSTANCE LINKED TO A BIOTIN FRACTION, AND COMPOSITION FOR ORAL ADMINISTRATION COMPRISING IT | |
WO2020092884A3 (en) | Cross-linked supramolecular nanoparticles for controlled release of antifungal drugs and steroids - a new therapeutic approach for onychomycosis and keloid | |
EP2345408A3 (en) | Acid labile drug formulations | |
WO2009087657A3 (en) | Stable pharmaceutical composition of duloxetine and process for its preparation | |
WO2017064652A3 (en) | Low dose oral dipyridamole compositions and uses thereof | |
WO2020190900A8 (en) | Abiraterone-cyclic oligomer pharmaceutical formulations and methods of formation and administration thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20776349 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20776349 Country of ref document: EP Kind code of ref document: A2 |